181 related articles for article (PubMed ID: 31027611)
1. Do increased tumor infiltrating lymphocytes co-existing with Homologous Recombination Deficiency provide clues to enhance immunotherapy of ovarian cancer?
Ledermann JA
Gynecol Oncol; 2019 May; 153(2):213-214. PubMed ID: 31027611
[No Abstract] [Full Text] [Related]
2. BRCA1/2 signaling and homologous recombination deficiency in breast and ovarian cancer.
Royfman R; Whiteley E; Noe O; Morand S; Creeden J; Stanbery L; Hamouda D; Nemunaitis J
Future Oncol; 2021 Jul; 17(21):2817-2830. PubMed ID: 34058833
[TBL] [Abstract][Full Text] [Related]
3. Combined PARP and Immune Checkpoint Inhibition in Ovarian Cancer.
Lee EK; Konstantinopoulos PA
Trends Cancer; 2019 Sep; 5(9):524-528. PubMed ID: 31474356
[TBL] [Abstract][Full Text] [Related]
4. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Turk AA; Wisinski KB
Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
[TBL] [Abstract][Full Text] [Related]
5. Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?
Gourley C; Miller RE; Hollis RL; Ledermann JA
Curr Opin Oncol; 2020 Sep; 32(5):442-450. PubMed ID: 32796232
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
Tan DS; Kaye SB
Am Soc Clin Oncol Educ Book; 2015; ():114-21. PubMed ID: 25993149
[TBL] [Abstract][Full Text] [Related]
7. Rucaparib Approved for Ovarian Cancer.
Cancer Discov; 2017 Feb; 7(2):120-121. PubMed ID: 28057616
[TBL] [Abstract][Full Text] [Related]
8. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.
Färkkilä A; Gulhan DC; Casado J; Jacobson CA; Nguyen H; Kochupurakkal B; Maliga Z; Yapp C; Chen YA; Schapiro D; Zhou Y; Graham JR; Dezube BJ; Munster P; Santagata S; Garcia E; Rodig S; Lako A; Chowdhury D; Shapiro GI; Matulonis UA; Park PJ; Hautaniemi S; Sorger PK; Swisher EM; D'Andrea AD; Konstantinopoulos PA
Nat Commun; 2020 Mar; 11(1):1459. PubMed ID: 32193378
[TBL] [Abstract][Full Text] [Related]
9. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Application of PARP Inhibitors in Neuro-Oncology.
Ning J; Wakimoto H
Trends Cancer; 2020 Feb; 6(2):147-159. PubMed ID: 32061304
[TBL] [Abstract][Full Text] [Related]
11. PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy.
Matsumoto K; Nishimura M; Onoe T; Sakai H; Urakawa Y; Onda T; Yaegashi N
Jpn J Clin Oncol; 2019 Aug; 49(8):703-707. PubMed ID: 31242303
[TBL] [Abstract][Full Text] [Related]
12. Olaparib, a new hope for ovarian cancer.
Samoon Z; Jabbar AA
Indian J Cancer; 2020; 57(3):346-347. PubMed ID: 32675438
[No Abstract] [Full Text] [Related]
13. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
[TBL] [Abstract][Full Text] [Related]
14. Should all advanced BRCA-mutated patients in response to first-line platinum-based chemotherapy receive PARPi + bevacizumab as maintenance therapy?
Turinetto M; Ray-Coquard I; Gourley C
ESMO Open; 2024 May; 9(5):102983. PubMed ID: 38663167
[No Abstract] [Full Text] [Related]
15. [BRCA1 and BRCA2 - pathologists starting kit].
Škapa P
Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
[TBL] [Abstract][Full Text] [Related]
16. Further Analyses Highlight Benefits of PARP Inhibitors As Frontline Maintenance in Ovarian Cancer.
Wright KM
Oncology (Williston Park); 2020 May; 34(5):175. PubMed ID: 32644177
[TBL] [Abstract][Full Text] [Related]
17. Niraparib Slows Ovarian Cancer Progression.
Cancer Discov; 2016 Dec; 6(12):OF2. PubMed ID: 27810860
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance.
Oda K; Tanikawa M; Sone K; Mori-Uchino M; Osuga Y; Fujii T
Int J Clin Oncol; 2017 Aug; 22(4):611-618. PubMed ID: 28508305
[TBL] [Abstract][Full Text] [Related]
19. Immune System and DNA Repair Defects in Ovarian Cancer: Implications for Locoregional Approaches.
Farolfi A; Gurioli G; Fugazzola P; Burgio SL; Casanova C; Ravaglia G; Altavilla A; Costantini M; Amadori A; Framarini M; Ansaloni L; De Giorgi U
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31130614
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status.
Saravi S; Alizzi Z; Tosi S; Hall M; Karteris E
Cells; 2021 Sep; 10(9):. PubMed ID: 34572083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]